Article | Open access | Published:
Scientific Reports volume 6, Article number: 19821 (2016)
https://doi.org/10.1038/srep19821
Blocking protein phosphatase 2A signaling prevents endothelial-to-mesenchymal transition and renal fibrosis: a peptide-based drug therapy
| 期刊: Scientific Reports | 发表时间: 2016-01-25 | 影响因子: 5.228 | ||
| 作者列表: Deng Yuanjun, Guo Yanyan, Liu Ping, Zeng Rui, Ning Yong, Pei Guangchang, Li Yueqiang, Chen Meixue, Guo Shuiming, Li Xiaoqing, Han Min, Xu Gang | ||||
| 第一作者国家: 中国 | 第一作者单位: 华中科技大学同济医学院附属同济医院 | |||
| 通讯作者国家: 中国 | 通讯作者单位: | |||
研究领域:药理学 肾病学 细胞生物学 分子生物学
关键字:蛋白磷酸酶2A 内皮-间充质转化 肾纤维化 肽基药物疗法 酪氨酸硝化 TAT-Y127WT
Endothelial-to-mesenchymal transition (EndMT) contributes to the emergence of fibroblasts and plays a significant role in renal interstitial fibrosis. Protein phosphatase 2A (PP2A) is a major serine/threonine protein phosphatase in eukaryotic cells and regulates many signaling pathways. However, the significance of PP2A in EndMT is poorly understood. In present study, the role of PP2A in EndMT was evaluated. We demonstrated that PP2A activated in endothelial cells (EC) during their EndMT phenotype acquisition and in the mouse model of obstructive nephropathy (i.e., UUO). Inhibition of PP2A activity by its specific inhibitor prevented EC undergoing EndMT. Importantly, PP2A activation was dependent on tyrosine nitration at 127 in the catalytic subunit of PP2A (PP2Ac). Our renal-protective strategy was to block tyrosine127 nitration to inhibit PP2A activation by using a mimic peptide derived from PP2Ac conjugating a cell penetrating peptide (CPP: TAT), termed TAT-Y127WT. Pretreatment withTAT-Y127WT was able to prevent TGF-β1-induced EndMT. Administration of the peptide to UUO mice significantly ameliorated renal EndMT level, with preserved density of peritubular capillaries and reduction in extracellular matrix deposition. Taken together, these results suggest that inhibiting PP2Ac nitration using a mimic peptide is a potential preventive strategy for EndMT in renal fibrosis.
本研究中,武汉百意欣生物技术有限公司(现武汉天德生物科技有限公司)协助提供多肽合成服务。“我们合成了 Y127WT(序列:ITQVYGFYD)及其随机打乱序列的变体肽 Y127Scr(序列:TYGVIYQFD),同时也合成了 Y130WT、Y265WT、Y267WT 和 Y284WT。在全身成像实验中,通过 N 端额外引入的一个赖氨酸残基,将异硫氰酸荧光素(FITC)与这些多肽进行偶联。所有多肽均使用固相合成仪,基于芴甲氧羰基(Fmoc)化学法进行合成,随后经高效液相色谱(HPLC)纯化,并通过质谱技术确认了它们的序列与结构。(由武汉百意欣生物技术有限公司提供,中国武汉)“(Y127WT (ITQVYGFYD) and its randomly scrambled variant peptide Y127Scr (TYGVIYQFD) were synthesized. Meanwhile, Y130WT, Y265WT, Y267WT and Y284WT were synthesized. Fluorescein iso-thiocyanate (FITC) was coupled to the peptides via an additional lysine at the N-terminus in whole-body imaging experiments. The peptides were synthesized using fluorenylmethyloxy carbonyl chloride chemistry in a solid-phase synthesizer and purified by high-performance liquid chromatography and their sequences and structures were confirmed by mass spectrometry (Wuhan Bai yixin Bio-tech Ltd., Wuhan, China).)。
